Renalytix uses cookies to improve your experience. We respect your privacy and are committed to protecting your personal data. Read Privacy Notice

Renalytix to Present at the 41st Annual Canaccord Genuity Global Growth Conference


Renalytix to Present at the 41st Annual Canaccord Genuity Global Growth Conference

NEW YORK, July 26, 2021 (GLOBE NEWSWIRE) — Renalytix plc (LSE: RENX) (NASDAQ: RNLX) (“Renalytix” or the “Company”) today announced the company will be presenting at the upcoming 41st Annual Canaccord Genuity Virtual Global Growth Conference.

Renalytix’s management is scheduled to present at the Canaccord Genuity Global Growth Conference on Wednesday, August 11 at 2:30pm EDT. Interested parties may access a live and archived webcast of the presentations on the “Investors” section of the company website at

For further information, please contact:

UK Investor Contact:

Walbrook PR Limited Tel: 020 7933 8780 or
Paul McManus / Lianne Cawthorne Mob: 07980 541 893 / 07584 391 303

US Investor Contact:

Gilmartin Group
Carrie Mendivil / Mary Kate McDonough 415-937-5405

About Renalytix
Renalytix is a developer of artificial intelligence-enabled clinical in vitro diagnostic solutions for kidney disease, one of the most common and costly chronic medical conditions globally. Renalytix’s products are being designed to make significant improvements in kidney disease diagnosis, transplant management, clinical care, patient stratification for drug clinical trials, and drug target discovery. For more information, visit

Help Me Spread The Post

If you enjoyed this post, we’d be grateful if you would help us spread its content.

Leave a comment

We’d love to hear your thoughts about this topic or any others. Please leave your comments below.

Note: your email address will not be published.

Well Filtered™

Get access to the blog, webinars and podcasts with the ideas, perspectives and innovations that matter most in kidney health.